Speaker Profile
Ph.D., Director, Personalized Medicine Operations, Sarah Cannon and Sarah Cannon Research Institute
Biography
Holli Hutcheson Dilks joined Sarah Cannon in 2014 as the Director of Personalized Medicine Operations. She is responsible for providing scientific support and direction for the development and implementation of Sarah Cannon’s global Molecular Profiling/Personalized Medicine Initiative. Additionally, she is responsible for the development of biomarker strategies in support of disease area programs and individual clinical trials. Previously, Dilks served as Technical Director of the Vanderbilt Technologies for Advanced Genomics Core Resource and Director of Core Resources at the Center for Human Genetics Research at Vanderbilt University Medical Center. She also served as a faculty member at Lipscomb University College of Pharmacy and a Program Director for SRI International. Dilks received her B.A. from Lipscomb University, her Ph.D. in Molecular Physiology and Biophysics from Vanderbilt University, and performed her postdoctoral Cancer Research Training Award fellowship at the National Cancer Institute (NIH). During her fellowship, she served as a visiting scientist at the Broad Institute of MIT and Harvard. In addition to her role at Sarah Cannon, Dilks currently serves as an Adjoint Assistant Professor for the Department of Pharmaceutical Sciences at Lipscomb University College of Pharmacy.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: While Precision Medicine is starting to deliver on some of its promise, hurdles still remain. Viewing interpreted genomic data within the context of a patient’s clinical record is challenging enough, but how do we add meaningful information into the existing workflow to inform a provider when a genetic test makes sense for their patient? And how do we make it easy to ingest the interpreted results to lead to better informed treatment decisions? In this session we will hear from a panel of industry leaders on the clinical, technical, organizational and political barriers that exist in the clinical enablement of precision medicine.
